Use of a composition in the preparation of a product for improving intestinal development

Abstract

The present invention provides an application of a composition in the preparation of a product for improving intestinal development; the composition comprises 1 to 10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide. The composition of whey protein powder rich in milk fat globule membrane and whey protein powder rich in caseinoglycomacropeptide with a mass ratio of (1-10):1 provided by the present invention has a synergistic effect on promoting intestinal development and can significantly increase the villus height of the intestine and the intestinal villus crypt ratio.

Description

Technical Field

[0001] The present invention relates to the field of food technology, and in particular to the application of a composition in the preparation of a product for improving intestinal development. Background Art

[0002] Phospholipids, as a type of milk fat, can promote the absorption and transport of fat digestion products in the digestive tract. At the same time, they are also involved in functions such as immune regulation and nerve signal conduction in the body, and promote brain development and maturation. Phospholipids in milk are found in two structures: milk fat globule membrane (MFGM) and exosomes (nanovesicles), and most phospholipids are present in the milk fat globule membrane (60%-70%). The milk fat globule membrane is a three-layer membrane structure that wraps the fat globule, and its function is to prevent the aggregation of fat globules and make them emulsified and dispersed in milk. In addition to phospholipids, the milk fat globule membrane also contains more than 200 kinds of proteins, cholesterol, enzymes and other trace components. Due to its complex variability in composition and structure, it is currently mainly monitored by the phospholipid concentration and the presence of membrane proteins. MFGM is mainly composed of various active lipids and proteins, originating from the endoplasmic reticulum membrane, apical plasma membrane and cytoplasmic compartments of mammary epithelial cells during lactation, accounting for 2%-6% of the mass of milk fat globules. The lipid components on MFGM are mainly divided into neutral lipids and polar lipids. Polar lipids account for 26%-40% of the MFGM lipid components, including glycerophospholipids [phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylinositol (PI)] and sphingolipids [especially sphingomyelin (SM)]. Among them, the contents of PE, PC, and SM are more abundant, while the contents of PS and PI are less. The main functions of polar lipids are to regulate lipid metabolism and participate in nervous system activities. Neutral lipids include triglycerides, sterols and sterol esters (mainly cholesterol), glycosphingolipids (cerebrosides and gangliosides), as well as diglycerides, monoglycerides, free fatty acids, etc. Among them, triglycerides account for 56%-62% of the MFGM lipid components and are the non-membrane lipid components during the separation and purification of MFGM.

[0003] Sialic acid is generally located at the end of macromolecules such as glycoproteins and glycolipids and is an important component of glycoproteins and glycolipids on cell membranes. Breast milk contains 0.3-1.5 mg / ml of sialic acid, mainly in the bound form, including human milk oligosaccharides, glycolipids and glycoproteins, with human milk oligosaccharides being the main form, accounting for 75% of the total sialic acid in breast milk. Sialic acid has a variety of biological functions: cell proliferation, differentiation and recognition; interaction with pathogenic microorganisms and participation in immune responses; promotion of nervous system development, facilitation of memory formation and improvement of learning ability.

[0004] In the prior art, the effect of compounding milk fat globule membrane and caseinoglycomacropeptide for intestinal development is still unclear and further research is needed.

[0005] At present, in the fields of infant formula foods, children's foods, complementary foods and nutritional supplements, there is a need for solutions to relieve intestinal discomfort and enhance intestinal development ability. Summary of the Invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide a composition that can improve intestinal development.

[0007] The present invention provides the use of the composition in the preparation of a product for improving intestinal development; the composition comprises 1 to 10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide.

[0008] Preferably, the composition comprises 5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide.

[0009] Preferably, the content of phospholipids in the whey protein powder rich in milk fat globule membrane is not less than 4 wt%; the content of sialic acid in the whey protein powder rich in caseinoglycomacropeptide is not less than 3 wt%.

[0010] Preferably, the product comprises infant formula food and / or children's formula food.

[0011] Preferably, in the infant formula food in terms of dry matter, the total protein content is 8 g to 20 g / 100 g, and the proportion of whey protein in the total protein is 40% to 80%; the fat content is 15 g to 30 g / 100 g; the carbohydrate content is 50 g to 70 g / 100 g;

[0012] The content of linoleic acid is 2700 to 4500 mg / 100 g, and the content of α-linolenic acid is 270 to 450 mg / 100 g.

[0013] Preferably, the infant formula food further comprises one or more of nutrients, dietary fiber, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin, OPO, casein calcium peptide or casein phosphopeptide.

[0014] Preferably, in the children's formula food in terms of dry matter, the total protein content is higher than 16.5 g / 100 g;

[0015] The children's formula food further comprises one or more of nutrients, dietary fiber, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin, OPO, casein calcium peptide or casein phosphopeptide.

[0016] Preferably, the improvement of intestinal development includes increasing the height of intestinal villi and / or increasing the depth of crypts.

[0017] Preferably, the improvement of intestinal development includes increasing the villus-crypt ratio.

[0018] Preferably, the intestine is jejunum and / or ileum.

[0019] Compared with the prior art, the present invention provides an application of a composition in the preparation of a product for improving intestinal development; the composition comprises 1-10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide. The composition of whey protein powder rich in milk fat globule membrane and whey protein powder rich in caseinoglycomacropeptide with a mass ratio of (1-10):1 provided by the present invention has a synergistic effect on promoting intestinal development, and can significantly increase the villus height of the intestine and the villus-crypt ratio of the intestinal villus. Description of the Drawings

[0020] Figure 1 shows the change of body weight of piglets;

[0021] Figure 2 shows the weight gain of piglets;

[0022] Figure 3 shows the feed intake result graph of piglets;

[0023] Figure 4 shows the result graph of the total weight and length of the small intestine;

[0024] Figure 5 shows the result graph of the length and weight of the small intestine of each group;

[0025] Figure 6 shows the result graph of the villus length and crypt depth of the duodenum, jejunum and ileum;

[0026] Figure 7 shows the result graph of the villus length, crypt depth and villus-crypt ratio of the small intestine;

[0027] Figure 8 shows the result graph of the villus length, crypt depth and villus-crypt ratio of the jejunum;

[0028] Figure 9 shows the result graph of the villus length, crypt depth and villus-crypt ratio of the ileum. Detailed Embodiments

[0029] The present invention provides the use of a composition in the preparation of a product for improving intestinal development. Those skilled in the art can draw on the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments. Relevant personnel can obviously make changes or appropriate changes and combinations to the methods and applications in this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0030] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there can be three relationships. For example, A and / or B can represent: A exists alone, A and B exist simultaneously, and B exists alone. Where A and B can be singular or plural.

[0031] In this application, "at least one" means one or more; "a variety of" means two or more. "At least one of the following" or its similar expression means any combination of these items, including any combination of single item (s) or plural items (s).

[0032] It should be understood that in various embodiments of this application, the size of the serial numbers of the above processes does not mean the order of execution. Some or all of the steps can be executed in parallel or sequentially. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation to the implementation process of the embodiments of this application.

[0033] The use of the composition provided by the present invention in the preparation of a product for improving intestinal development; the composition includes 1 to 10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide.

[0034] In some preferred embodiments of the present invention, the composition includes 1 to 8 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide.

[0035] In some preferred embodiments of the present invention, the composition includes 2.5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide.

[0036] In some preferred embodiments of the present invention, the composition includes 3.5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide.

[0037] In some preferred embodiments of the present invention, the composition comprises 4.5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinomacropeptide.

[0038] In some preferred embodiments of the present invention, the composition comprises 5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinomacropeptide.

[0039] The present invention creatively discovers that the whey protein powder containing milk fat globule membrane and the whey protein powder rich in caseinomacropeptide in the above proportions can improve intestinal development.

[0040] The product of the present invention includes infant formula food and / or children's formula food.

[0041] The food of the present invention preferably includes dairy products.

[0042] The dairy products of the present invention include liquid milk (pasteurized milk, sterilized milk, formulated milk, fermented milk); milk powder (whole milk powder, skim milk powder, partially skimmed milk powder, formulated milk powder, colostrum powder); other dairy products. Specifically, it can be: The first category is liquid milk. It mainly includes sterilized milk, sterilized milk, yogurt, etc. The second category is milk powder. It includes whole milk powder, skim milk powder, whole milk powder with added sugar, flavored milk powder, infant milk powder and other formula milk powders. The third category is condensed milk. The fourth category is milk fat. It includes light cream for making cakes, common cream for eating with bread, etc. The fifth category is cheese. The sixth category is milk ice cream. The seventh category is other dairy products. It mainly includes casein, lactose, milk tablets, etc.

[0043] The dairy products of the present invention preferably include one or more of formulated milk, formulated milk powder, fermented milk, milk tablets, cheese or milk snacks.

[0044] According to the specific embodiments of the present invention, in the dry matter equivalent of the infant formula food of the present invention, the total protein content is 8 g to 20 g / 100 g, and the proportion of whey protein in the total protein is 40% to 70%; the fat content is 15 g to 30 g / 100 g; the carbohydrate content is 50 g to 70 g / 100 g; preferably, in the dry matter equivalent of the infant formula food of the present invention, the total protein content is 10 g to 18 g / 100 g; the proportion of whey protein in the total protein is 40% - 65%; the fat content is 18 g to 28 g / 100 g; the carbohydrate content is 52 g to 60 g / 100 g..

[0045] According to specific embodiments of the present invention, in the dry matter equivalent of the infant formula food of the present invention, it further contains linoleic acid and α-linolenic acid, with the linoleic acid content being 2700 - 4500 mg / 100 g and the α-linolenic acid content being 270 - 450 mg / 100 g.

[0046] According to specific embodiments of the present invention, the infant formula food in the present invention can be a formula food for infants aged 0 - 6 months, a formula food for older infants aged 6 - 12 months, or a formula food for toddlers aged 12 - 36 months.

[0047] Specifically, in the dry matter equivalent of the formula food for infants aged 0 - 6 months, the total protein content is 8 - 15 g / 100 g, the proportion of whey protein in the total protein is 60 - 70%, the fat content is 23 - 30 g / 100 g, the linoleic acid content is 2700 - 4500 mg / 100 g, the α-linolenic acid content is 270 - 450 mg / 100 g, and the carbohydrate content is 50 - 60 g / 100 g.

[0048] In the dry matter equivalent of the formula food for older infants aged 6 - 12 months, the total protein content is 8 - 20 g / 100 g, the proportion of whey protein in the total protein is 40 - 70%, the fat content is 20 - 30 g / 100 g, the linoleic acid content is 2700 - 4500 mg / 100 g, the α-linolenic acid content is 270 - 450 mg / 100 g, and the carbohydrate content is 50 - 60 g / 100 g.

[0049] In the dry matter equivalent of the formula food for toddlers aged 12 - 36 months, the total protein content is 8 - 20 g / 100 g, the fat content is 20 - 30 g / 100 g, the linoleic acid content is 2700 - 4500 mg / 100 g, the α-linolenic acid content is 270 - 450 mg / 100 g, and the carbohydrate content is 50 - 60 g / 100 g.

[0050] According to specific embodiments of the present invention, in the infant formula food of the present invention, the raw materials providing total protein include: raw milk (cow / sheep), whole milk powder (cow / sheep), skim milk powder (cow / sheep), whey protein powder (cow / sheep), demineralized whey powder (cow / sheep), and one or more of β-casein. Specifically, based on 1000 parts by weight of the above-mentioned infant formula food, its raw materials include: 0 - 3500 parts of raw milk (cow / sheep), 0 - 260 parts of whole milk powder (cow / sheep), 0 - 120 parts of whey protein powder (cow / sheep), 0 - 400 parts of skim milk powder (cow / sheep), and / or 0 - 600 parts of demineralized whey powder (cow / sheep), and the addition amount of β-casein is 0 - 40 parts.

[0051] According to the specific embodiments of the present invention, in the infant formula food of the present invention, the raw materials providing fat include one or more of the following raw materials in parts by weight: 0-50 parts of corn oil, 0-65 parts of soybean oil, 0-100 parts of sunflower seed oil, 0-240 parts of 1,3-diolein-2-palmitin, 0-30 parts of coconut oil, 0-85 parts of rapeseed oil with low erucic acid, and 0-20 parts of linseed oil.

[0052] According to the specific embodiments of the present invention, in the infant formula food of the present invention, the raw materials providing carbohydrates include: 0-500 parts of lactose, and / or the above-mentioned protein raw materials containing lactose.

[0053] According to the specific embodiments of the present invention, in the infant formula food of the present invention, in addition to the above components, it may further include the conventional components of infant formula food, for example, it may further include one or more of nutrients, dietary fiber, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin. Preferably, it includes a compound nutrient package. In some preferred embodiments, the infant formula food includes 0-20 parts of nutrients, and the nutrients include vitamins and minerals, or further selectively includes one or more of dietary fiber (fructooligosaccharide, galactooligosaccharide, polydextrose, etc.), inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin, probiotics. The compound nutrients mainly include: compound vitamins: one or more of vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B 12 , niacin, folic acid, pantothenic acid, vitamin C, choline, biotin; compound minerals: sodium, potassium, calcium, phosphorus, copper, iron, zinc, manganese, iodine, selenium, magnesium, potassium and their derivatives. The sources, contents and usage amounts of the various vitamins and minerals in the present invention all comply with the national standards and relevant regulations for infant formula food.

[0054] In the dry matter equivalent of the children's formula food of the present invention, the total protein content is higher than 16.5 g / 100 g. According to the specific embodiments of the present invention, in the children's formula food of the present invention, the raw materials providing total protein include: raw milk (cow / sheep), whole milk powder (cow / sheep), skim milk powder (cow / sheep), whey protein powder (cow / sheep), demineralized whey powder (cow / sheep), and one or more of β-casein. Specifically, based on 1000 parts by weight of the above-mentioned infant formula food, its raw materials include: 0-3500 parts of raw milk (cow / sheep), 0-260 parts of whole milk powder (cow / sheep), 0-120 parts of whey protein powder (cow / sheep), 0-400 parts of skim milk powder (cow / sheep), and / or 0-600 parts of demineralized whey powder (cow / sheep), and the addition amount of β-casein is 0-40 parts.

[0055] Among them, the children's formula food also includes one or more of nutrients, dietary fiber, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin, OPO, casein calcium peptide, and casein phosphopeptide.

[0056] According to a specific embodiment of the present invention, in the milk fat globule membrane and caseinoglycomacropeptide composition applied to the preparation of infant formula food of the present invention, the milk fat globule membrane and caseinoglycomacropeptide are provided by whey protein powder, and the phospholipid content in the whey protein powder (rich in milk fat globule membrane) is not less than 4 wt%. The sialic acid content in the whey protein powder (rich in caseinoglycomacropeptide) is not less than 3 wt%.

[0057] The improvement of intestinal development described in the present invention includes increasing the intestinal villus height and / or increasing the crypt depth.

[0058] The improvement of intestinal development described in the present invention includes increasing the villus-crypt ratio.

[0059] The intestine described in the present invention is the jejunum and / or ileum.

[0060] According to a specific embodiment of the present invention, the infant formula food of the present invention has the effect of promoting intestinal development.

[0061] According to a specific embodiment of the present invention, in the application of the composition of the present invention, the organism includes animals or humans.

[0062] The infant formula food of the present invention has the effect of promoting intestinal development due to the composition including the milk fat globule membrane and caseinoglycomacropeptide.

[0063] On the other hand, the present invention also provides a method for preparing the infant formula food. The method adopts a wet or dry production process, mixes the milk fat globule membrane and caseinoglycomacropeptide composition with other raw materials in the formula to prepare the formula food. The main process flow of its preparation mainly includes: batching, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain the finished product. In the present invention, the milk fat globule membrane and caseinoglycomacropeptide can be mixed together during batching, or added during the post-mixing process.

[0064] In summary, the present invention discovers that the composition including the milk fat globule membrane and caseinoglycomacropeptide has the effect of promoting intestinal development, can increase the intestinal villus height and / or the intestinal villus-crypt ratio, and has a broad application prospect when applied to infant formula food.

[0065] The following further elaborates the present invention in combination with examples:

[0066] Example 1

[0067] This embodiment provides a powdered infant formula for infants aged 0 to 6 months. The total protein content in this powdered formula is 10.7 g / 100 g of powder, the fat content is 27.9 g / 100 g of powder; the carbohydrate content is 55.2 g / 100 g of powder; probiotics are 1×10 8 CFU / 100 g of powder; milk fat globule membrane: casein glycopeptide = 9:1.

[0068] This embodiment is achieved by compounding the following raw materials by weight. Its raw material composition includes (preparing 1000 parts by weight):

[0069] 1000 parts of raw cow milk, 77 parts of lactose, 120 parts of mixed vegetable oil, 110 parts of OPO structured oil, 485 parts of demineralized whey powder, 20 parts of skimmed milk powder, 18 parts of whey protein powder (rich in milk fat globule membrane), 2 parts of whey protein powder (rich in casein glycopeptide), 33 parts of galactooligosaccharide, 24 parts of fructooligosaccharide, 0.18 parts of probiotics, 2.5 parts of compound vitamins, and 8 parts of compound minerals.

[0070] The infant formula powder of this embodiment is prepared by a dry production process, which mainly includes: batching, preheating, homogenization, concentration sterilization, spray drying, and dry mixing with the addition of probiotics to obtain the finished product. After testing, the various indicators of this finished product meet the requirements of the infant formula food standard.

[0071] Example 2

[0072] This embodiment provides a powdered formula food for older infants aged 6 to 12 months. The total protein content in this powdered formula is 12.5 g / 100 g of powder, the fat content is 22.9 g / 100 g of powder; the carbohydrate content is 57.9 g / 100 g of powder, and probiotics are 1.5×10 9 CFU / 100 g of powder; milk fat globule membrane: casein glycopeptide = 7:1.

[0073] This embodiment is achieved by compounding the following raw materials by weight. Its raw material composition includes (preparing 1000 parts by weight):

[0074] 2000 parts of raw cow milk, 235 parts of demineralized whey powder, 239 parts of lactose, 100 parts of skimmed milk powder, 150 parts of mixed vegetable oil (including OPO structured fat), 14 parts of whey protein powder (rich in milk fat globule membrane), 2 parts of whey protein powder (rich in casein glycopeptide), 0.5 parts of Bifidobacterium lactis, 3 parts of compound vitamins, and 6 parts of compound minerals.

[0075] The formula food for older infants of this embodiment is prepared by a dry production process, which mainly includes: batching, preheating, homogenization, concentration sterilization, spray drying, and dry mixing with the addition of probiotics to obtain the finished product. After testing, the various indicators of this finished product meet the requirements of the formula food standard for older infants.

[0076] Example 3

[0077] This example provides a powdered infant formula goat milk powder for 12 - 36 - month - old infants. In this powdered formula food, the total protein content is 13.8 g / 100 g powder, the fat content is 23.5 g / 100 g powder; the carbohydrate content is 57.5 g / 100 g powder; probiotics are 1×10 9 CFU / 100 g powder. Milk fat globule membrane: casein glycopeptide = 6:1. This example is achieved by compounding the following raw materials by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0078] 1900 parts of raw goat milk, 325 parts of demineralized whey powder, 140 parts of lactose, 140 parts of mixed vegetable oil (including OPO structured lipid), 33 parts of whey protein powder WPC80, 12 parts of whey protein powder (rich in milk fat globule membrane), 2 parts of whey protein powder (rich in casein glycopeptide), 85 parts of galactooligosaccharide, 13 parts of fructooligosaccharide, 0.33 parts of probiotics, 3 parts of compound vitamins, and 6 parts of compound minerals.

[0079] The infant formula powder in this example is prepared by a dry - process production process, which mainly includes: batching, pre - heating, homogenization, concentration and sterilization, spray drying, and dry - mixing with the addition of probiotics to obtain the finished product. After testing, the various indicators of this finished product meet the requirements of the infant formula food standard.

[0080] Example 4

[0081] This example provides a powdered children's formula goat milk powder. In this powdered formula food, the total protein content is 17.5 g / 100 g powder, the fat content is 21 g / 100 g powder; the carbohydrate content is 50.5 g / 100 g powder; HN019 probiotics are 1×10 9 CFU / 100 g powder. Milk fat globule membrane: casein glycopeptide = 5:1.

[0082] This example is achieved by compounding the following raw materials by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0083] 430 parts of whole - fat goat milk powder, 425 parts of demineralized whey powder (from goat milk), 4 parts of lactose, 60 parts of mixed vegetable oil (including OPO structured lipid), 20 parts of whey protein powder WPC80, 10 parts of whey protein powder (rich in milk fat globule membrane), 2 parts of whey protein powder (rich in casein glycopeptide), 30 parts of galactooligosaccharide, 25 parts of fructooligosaccharide, 0.33 parts of Bifidobacterium lactis, 3 parts of compound vitamins, and 6 parts of compound minerals.

[0084] The infant formula powder of this embodiment is prepared by a dry production process, which mainly includes: batching, preheating, homogenization, concentration sterilization, spray drying, dry mixing and adding probiotics to obtain the finished product. After testing, the various indicators of the finished product meet the requirements of the formulated milk powder food standard.

[0085] Verification example

[0086] Efficacy experiment of milk fat globule membrane and caseinoglycomacropeptide composition

[0087] Example

[0088] 1. Sample

[0089] The milk fat globule membrane (MFGM) and caseinoglycomacropeptide (CGMP) in this study mainly come from whey powder rich in MFGM and CGMP. By adjusting the addition amount of the two kinds of whey powder, the test formula powder with different proportions is made. Among them, the whey protein powder rich in milk fat globule membrane (MFGM) has a protein content of 69-76wt%, a fat content of 16-22wt%, and a phospholipid content of 6-10wt%; in the whey protein powder rich in caseinoglycomacropeptide (CGMP), the CGMP content is 60-80wt%, and the sialic acid content is 4-6wt%.

[0090] According to the nutritional needs of neonatal piglets, various required nutrients are added to make the basic formula milk powder to ensure the normal growth of piglets. The specific formula of the basic formula milk powder is shown in Table 1.

[0091] Table 1

[0092]

[0093]

[0094] 2. Preliminary preparation

[0095] 2.1 Experimental animals

[0096] Newborn 2-day-old ordinary male three-way hybrid piglets are used in the experiment. The weight range of the piglets is 1.3-2.0 kg, and 10 piglets are included in each experimental group, with a total of 80.

[0097] 2.2 Animal feeding conditions

[0098] The feeding conditions of the piglets are carried out in accordance with the national standard GB14925-2010 of the People's Republic of China. Specifically:

[0099] Temperature: room temperature 16-26°C;

[0100] Humidity: relative humidity 40-70%;

[0101] Light: artificial lighting, 12-hour light and dark alternation;

[0102] Ventilation rate: ≥8 times per hour, 100% fresh air

[0103] Feeding method: 5 times a day, at 9 am, 1 pm, 5 pm, 9 pm and 1 am

[0104] 3 Experimental design

[0105] 3.1 Animal enrollment and feeding

[0106] Select neonatal male piglets at 2 days old, weighing 1.3 - 2.0 kg. According to the reproductive situation of sows, 5 - 10 piglets are placed in the room per batch. Adjust the daily feeding amount according to the weight of the piglets on the same day. Prepare the milk solution with warm water (37 - 40 °C) and re - prepare the milk solution every 4 - 5 hours. Feed the piglets until the 30th day after birth

[0107] 3.2 Grouping information

[0108] On the premise of the basic formula powder in Table 1, adjust the dosage and proportion of MFGM and CGMP, and finally form 8 formulas as follows

[0109] Table 2

[0110]

[0111] 3.3 Observation of piglet status and physiological indicators

[0112] During the experiment, track and observe the feeding, activity and rest of the piglets, and focus on observing their diarrhea situation. Record the fasting weight of the piglets every morning, calculate the daily food intake, and calculate the weight gain of the piglets during the entire experimental period

[0113] 3.4 Piglet intestinal tissue indicators

[0114] On the last day of the experiment (the 30th day of feeding), collect the intestinal samples of the piglets and analyze and measure the small intestine length, total weight, villus height, crypt depth, and villus - to - crypt ratio

[0115] 4 Experimental results

[0116] 4.1 Piglet physiological indicators

[0117] 1) Weight index

[0118] Record the initial weight of the piglets when they are enrolled, and record the weight of the piglets at a fixed time every day during the test stage to track the change of the piglets' weight (such as Figure 1 ).

[0119] Analysis of the weight gain of the piglets found that there was no significant difference in the weight gain of the animals during the experiment, indicating that the tested formulas can meet the normal growth needs of the piglets (such asFigure 2 )。

[0120] 2) Feed intake

[0121] Analysis of the feed intake of piglets found that the daily feed intake of piglets was positively correlated with body weight, and the change trends of the two were consistent, and there were no significant differences among groups (such as Figure 3 ), indicating that the test formula would not affect the daily feed intake of piglets.

[0122] 4.2 Intestinal tissue

[0123] (1) Total weight and length of the small intestine

[0124] The entire small intestine of piglets in Composition 1 was selected, and the length was measured with a tape measure. The weight of the small intestine was weighed with a platform scale (such as Figure 4 ). Since the length and weight of the small intestine vary greatly among animals of different body weights, the small intestine length (cm) / body weight (kg) and small intestine weight (g) / body weight (kg) were used for statistical analysis. There were no significant differences in the small intestine length and weight among groups ( Figure 5 ).

[0125] (2) Small intestine villus height (μm), crypt depth (μm), villus-crypt ratio

[0126] After fixing and embedding the intestinal tissue samples, the tissues were sectioned and stained, and the pathological changes of the duodenum (Composition 2), jejunum (Composition 1), and ileum (Composition 6) of the small intestine were observed under a microscope, and the villus length and crypt depth of the duodenum, jejunum, and ileum were measured ( Figure 6 ):

[0127] Analysis of the villus length, crypt depth, and villus-crypt ratio of the duodenum, jejunum, and ileum in each group to analyze the degree of intestinal development of piglets ( Figure 7 , Figure 8 and Figure 9 ). The results showed that there were no differences in the duodenal villus height, crypt depth, and small intestine villus-crypt ratio among groups.

[0128] While groups 6 and 7 could significantly increase the intestinal villus height and villus-crypt ratio of the jejunum and ileum, which were significantly higher than those of the control group and other groups. It shows that the MFGM+CGMP composition (groups 6 and 7) can promote the increase of intestinal villus height and promote the intestinal maturity of piglets. And compared with the single MFGM group (groups 2 and 3) and single CGMP (group 4), the MFGM+CGMP composition (groups 6 and 7) has a synergistic effect in promoting the intestinal villus development and intestinal maturity of piglets.

[0129] The above are only the preferred embodiments of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements should also be regarded as the protection scope of the present invention.

Claims

1. Use of a composition in the preparation of an infant formula food and / or a children's formula food for improving intestinal development; the composition comprises 5 to 9 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinomacropeptide; the improvement of intestinal development includes increasing the villus-crypt ratio, increasing the intestinal villus height and / or increasing the crypt depth; the intestine is the jejunum and / or the ileum; In the infant formula food in terms of dry matter, the total protein content is 8 g to 20 g / 100 g, and the proportion of whey protein in the total protein is 40% to 80%; the fat content is 15 g to 30 g / 100 g; the carbohydrate content is 50 g to 70 g / 100 g; The linoleic acid content is 2700 to 4500 mg / 100 g, and the α-linolenic acid content is 270 to 450 mg / 100 g; In the children's formula food in terms of dry matter, the total protein content is higher than 16.5 g / 100 g.

2. The application according to claim 1, characterized in that, The content of phospholipids in the whey protein powder rich in milk fat globule membrane is not less than 4 wt%; the content of sialic acid in the whey protein powder rich in caseinomacropeptide is not less than 3 wt%.

3. The application according to claim 1, wherein The infant formula food also includes one or more of dietary fiber, probiotics, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin, OPO, casein calcium peptide or casein phosphopeptide.

Images